Literature DB >> 19072688

Discovery of potent thermolysin inhibitors using structure based virtual screening and binding assays.

Mahmud Tareq Hassan Khan1, Ole-Martin Fuskevåg, Ingebrigt Sylte.   

Abstract

In the present work, 22 compounds of the U.S. NCI compound library (size 273K) were identified as putative thermolysin binders by structure based virtual screening with the ICM software (ICM-VLS). In vitro competitive binding assays confirmed that 12 were thermolysin binders. Thermolysin binding modes of the 12 compounds were studied by docking using ICM and Molegro Virtual Docker (MVD). The most potent inhibitor had an IC(50) value of 6.4 x 10(-8) mM (NSC250686, 1 beta-D-arabinofuranosyl-N(4)-lauroylcytosine). The structure of this compound is quite different from the other 11 compounds. Nine out of the 12 compounds contained a similar chemical skeleton (3-nitrobenzamide derivatives) and have IC(50) values ranging from 697.48 to 0.047 mM. The ICM-VLS score and the activity profiles (pIC(50) values) were compared and found to be somewhat linearly correlated (R(2) = 0.78). Kinetic studies showed that, except for NSC285166 (oxyquinoline), the compounds are competitive thermolysin inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19072688     DOI: 10.1021/jm8008019

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  The diterpenoid alkaloid noroxoaconitine is a Mapkap kinase 5 (MK5/PRAK) inhibitor.

Authors:  Sergiy Kostenko; Mahmud Tareq Hassan Khan; Ingebrigt Sylte; Ugo Moens
Journal:  Cell Mol Life Sci       Date:  2010-07-17       Impact factor: 9.261

2.  Docking and scoring with ICM: the benchmarking results and strategies for improvement.

Authors:  Marco A C Neves; Maxim Totrov; Ruben Abagyan
Journal:  J Comput Aided Mol Des       Date:  2012-05-09       Impact factor: 3.686

3.  Evaluation of new antihypertensive drugs designed in silico using Thermolysin as a target.

Authors:  Desmond MacLeod-Carey; Eduardo Solis-Céspedes; Emilio Lamazares; Karel Mena-Ulecia
Journal:  Saudi Pharm J       Date:  2020-04-02       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.